Jieruo Medical

Jieruo Medical Technology (Shanghai) Co., Ltd. focuses on developing vascular interventional surgery robots designed to assist physicians in performing percutaneous coronary intervention (PCI) and other catheter-based vascular procedures. Based in Shanghai’s G60 Science and Technology Innovation Corridor in Songjiang District, the company has positioned itself as a domestic competitor in China’s emerging vascular interventional robotics market.

Company Overview

Founded by CEO Shen Bifeng, Jieruo Medical originated as a medical device and consumables manufacturer before strategically pivoting to surgical robotics development. This background in interventional consumables has shaped the company’s approach to robot design, with systems engineered to be compatible with both proprietary consumables and conventional surgical instruments.

The company maintains its headquarters and R&D operations in Shanghai’s Songjiang District, situated within the G60 corridor that connects Shanghai with neighboring Jiangsu and Zhejiang provinces. This location places Jieruo Medical within one of China’s designated innovation hubs for advanced manufacturing and medical technology.

Technical Director Hong Jiong leads the engineering team responsible for the company’s robotic platform development. The team has focused on achieving sub-millimeter precision control, a critical requirement for coronary interventions where vessel movement during cardiac cycles creates positioning challenges.

Core Products

First-Generation Vascular Interventional Robot

Jieruo Medical’s flagship product is a PCI-focused surgical robot system designed to assist interventional cardiologists in stent placement, balloon angioplasty, and guidewire navigation procedures. The system features:

• Sub-millimeter positioning accuracy for precise device delivery
• Compatibility with standard interventional instruments
• Dedicated robotic consumables optimized for system performance
• Remote operation capability enabling potential telesurgery applications

The first-generation system completed multi-center registration clinical trials in 2023, with over 40 procedures performed at Wuhan University People’s Hospital’s Cardiovascular Disease Hospital under the supervision of Professor Jiang Xuejun and Dr. Qu Zhe.

Second-Generation Portable System (In Development)

The company has initiated development of a second-generation portable interventional robot characterized by reduced size and enhanced flexibility. According to company disclosures, production costs for this system are projected to decrease exponentially compared to the first-generation platform. Animal trials have commenced for this next-generation system.

Third-Generation Autonomous Robot (Early Stage)

Jieruo Medical has begun preliminary work on a third-generation fully autonomous robotic system, though this remains in early conceptual stages.

Technology & Innovation

The company’s core technical platform centers on precision control systems capable of sub-millimeter instrument manipulation. Professor Jiang Xuejun from Wuhan University People’s Hospital has characterized the system as offering “flexible, convenient remote control with enhanced procedural precision.”

Key technical capabilities include:

• Sub-millimeter Micro-adjustment: Enables precise stent positioning during cardiac cycles when vessels move approximately 1mm with each heartbeat
• Dual Compatibility Design: Supports both proprietary robotic consumables and conventional catheter-based instruments
• Radiation Reduction: Remote operation from shielded control stations reduces physician radiation exposure
• Procedure Time Optimization: Robotic assistance reported to shorten complex procedure duration while reducing operator fatigue

Clinical Applications

The primary clinical focus remains coronary artery intervention, including:

• Stent implantation for coronary artery disease
• Balloon angioplasty
• Complex lesion treatment including bifurcation and calcified lesions
• Chronic total occlusion procedures

Clinical feedback from trial procedures indicates the robotic system provides enhanced visualization of three-dimensional vessel anatomy compared to conventional two-dimensional fluoroscopic imaging, enabling more precise guidewire navigation.

Regulatory Status

As of the most recent available information (late 2023), Jieruo Medical had completed registration clinical trial enrollment for its first-generation vascular interventional robot. The company was preparing NMPA submission with approval anticipated in the 2024-2025 timeframe.

Market Position

Jieruo Medical operates within a competitive domestic landscape that includes several other Chinese companies developing vascular interventional robots:

• Microport MedBot’s Zhimai Robot (R-ONE, NMPA approved 2023)
• WeMed (ETcath system)
• Aibo Medical Robot
• Allpeng Medical

The company’s differentiation strategy emphasizes its consumables heritage, positioning the robot as part of an integrated equipment-plus-consumables ecosystem rather than a standalone robotic platform.

Key Milestones

• Company established in Shanghai Songjiang District
• First-generation PCI robot development initiated
• Multi-center clinical trials launched at Wuhan University People’s Hospital
• Completion of 40+ clinical trial procedures (2023)
• Registration clinical trial enrollment completed (2023)
• Second-generation portable robot enters animal trials

Frequently Asked Questions

What type of procedures can Jieruo Medical’s robot perform?

The system is designed primarily for percutaneous coronary interventions (PCI) including stent placement, balloon angioplasty, and guidewire navigation. The platform supports treatment of both simple and complex coronary lesions.

Has Jieruo Medical’s robot received regulatory approval?

As of late 2023, the company had completed registration clinical trials and was preparing for NMPA submission. Approval status for 2024-2025 has not been independently confirmed.

How does Jieruo Medical’s robot differ from competitors?

The company emphasizes its background in interventional consumables, designing systems compatible with both proprietary robotic consumables and conventional instruments. The second-generation portable design also aims to reduce system size and cost compared to competitors.